BrainStorm Cell Therapeutics Inc (BCLI)

[Fmello]

BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021

https://seekingalpha.com/pr/18502992-brainstorm-to-present-als-phase-3-biomarker-analyses-annual-neals-meeting-october-6th-2021

https://brainstorm-cell.com/wp-content/uploads/2021/10/NEALS-poster-2021.pdf

BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial" will be presented as a scientific poster at the fully digital 2021 Northeast Amyotrophic Lateral Sclerosis Consortium® (NEALS) conference. The presentation will be delivered by James Berry, M.D. MPH, Winthrop Family Scholar in ALS Sciences, Director of the Massachusetts General Hospital (MGH) multidisciplinary ALS clinic and Chief of the Division of ALS and Motor Neuron Diseases, Boston MA. The Phase 3 trial (NCT03280056) evaluated three repeated intrathecal administrations of NurOwn® (MSC-NTF cells), each given two months apart, as a treatment for amyotrophic lateral sclerosis (ALS). The presentation will highlight CSF biomarkers that demonstrate high accuracy in predicting the primary clinical outcome using an unbiased stepwise logistic regression analysis.

Presentation details:
Session Date: October 6th 2021
Presenting Time: 4:00pm – 5:00pm ET

"We are fully committed to advance our proprietary cell therapy NurOwn® in ALS" said Chaim Lebovits, Chief Executive Officer of BrainStorm. "We believe that making tangible progress in ALS science and clarifying the molecular signature of NurOwn's mechanism of action in ALS will be an important next step in bringing a much needed therapy to patients with ALS who have a terminal disease and have limited treatment options."

Stacy Lindborg, EVP and Head of Global Clinical Research at Brainstorm commented, "We are excited to show the significant changes of NurOwn across a range of biomarkers spanning important domains such as neurodegeneration, neuroinflammation and neuroprotection. Furthermore, by using biomarker response and an innovative statistical model, we can predict treatment outcomes in the study with great accuracy. These objective biomarker endpoints provide more confidence as we continue researching and developing NurOwn."

The poster will be available on the Publications page of Brainstorm's corporate website, following the presentation at the NEALS conference.

I hope there will be a link to the presentation so we can watch.